跳至主要内容
临床试验/NCT05983172
NCT05983172Enrolling By Invitation不适用

Multi-omics Approach of Risk Stratification for Patients With de Novo Acute Myeloid Leukemia

National Taiwan University Hospital1 个研究点 分布在 1 个国家目标入组 1,500 人开始时间: 2023年8月最近更新:
适应症

试验速览

阶段
不适用
状态
Enrolling By Invitation
入组人数
1,500
试验地点
1
主要终点
Overall survival

研究概览

简要总结

The investigators will use machine learning to identify features on bone marrow smears and select features that are related to gene mutations, gene expression, or prognosis. The investigators will then use genome-wide transcriptomic profiling to investigate gene expression that is associated with patients' outcomes. The investigators will design a next-generation sequencing panel with unique molecular index and assess its feasibility and robustness in detecting measurable residual disease and optimize the panel/platform/bioinformatic pipeline. Finally, The investigators will use machine learning to integrate bone marrow smear features, gene mutations, gene expression, and measurable residual disease to construct a comprehensive risk assessment system that is based on multi-omics data. The investigators believe that such a platform will help physicians to design the most appropriate treatment strategies for individual patients, not only advancing the concept of precision medicine but also improving patients' prognoses.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Other

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Diagnosed with acute myeloid leukemia at the National Taiwan University Hospital
  • Ever enrolled in 201802021RINC、202109078RINB、201709072RINC

排除标准

  • 未提供

结局指标

主要结局

Overall survival

时间窗: From date of diagnosis until the date of death from any cause, assessed up to 30 years

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

National Taiwan University Clinical Trial Center

Assistant Professor and attending physician

National Taiwan University Hospital

研究点 (1)

Loading locations...

相似试验